Keros Therapeutics (NASDAQ:KROS) Stock Price Down 5.7% on Analyst Downgrade

Keros Therapeutics, Inc. (NASDAQ:KROS)’s stock price traded down 5.7% during trading on Tuesday after Oppenheimer lowered their price target on the stock from $102.00 to $63.00. Oppenheimer currently has an outperform rating on the stock. Keros Therapeutics traded as low as $18.12 and last traded at $18.32. 350,670 shares changed hands during mid-day trading, a decline of 24% from the average session volume of 463,453 shares. The stock had previously closed at $19.42.

KROS has been the subject of a number of other research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. BTIG Research lowered shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 12th. Wells Fargo & Company raised their price objective on shares of Keros Therapeutics from $88.00 to $111.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Bank of America reduced their target price on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. Finally, HC Wainwright dropped their price target on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $81.33.

Institutional Trading of Keros Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Point72 Asset Management L.P. boosted its holdings in Keros Therapeutics by 155.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after buying an additional 577,220 shares during the period. Alkeon Capital Management LLC boosted its stake in shares of Keros Therapeutics by 18.7% in the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock worth $110,194,000 after acquiring an additional 298,694 shares during the period. Parkman Healthcare Partners LLC grew its position in shares of Keros Therapeutics by 112.3% during the third quarter. Parkman Healthcare Partners LLC now owns 421,782 shares of the company’s stock worth $24,493,000 after purchasing an additional 223,155 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in Keros Therapeutics by 814.6% during the 3rd quarter. Assenagon Asset Management S.A. now owns 223,704 shares of the company’s stock valued at $12,990,000 after purchasing an additional 199,245 shares during the period. Finally, FMR LLC lifted its holdings in Keros Therapeutics by 3.8% in the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company’s stock worth $284,493,000 after purchasing an additional 179,374 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Trading Down 7.3 %

The company has a 50 day simple moving average of $57.46 and a two-hundred day simple moving average of $52.30. The firm has a market capitalization of $729.13 million, a P/E ratio of -3.45 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company had revenue of $0.39 million during the quarter. During the same quarter in the prior year, the firm posted ($1.33) EPS. The firm’s quarterly revenue was up 4750.0% on a year-over-year basis. On average, sell-side analysts expect that Keros Therapeutics, Inc. will post -5.26 EPS for the current fiscal year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.